<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2402210540
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KROMAFINA 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        136.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ALPHA PHARMA INDUSTRY " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2732]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Alpha Pharma Industry
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Kromafina contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.<br />Kromaflna is used for:<br />٠ preventing nausea and vomiting caused by chemotherapy (in adults and<br />children) or radiotherapy for cancer (adults only).<br />٠ preventing nausea and vomiting after surgery (adults only).<br />Ask your doctor or pharmacist if you would like any further explanation about these uses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>٠ If you are allergic (hypersensitive) to ondansetron or any of the other ingredients of this medicine (listed in section 6)-<br />٠ If you are taking apomorphine (used to treat Parkinson&rsquo;s disease).</p><p>If you are not sure, talk to your doctor or pharmacist before taking Kromaflna.<br /><strong>Warnings and precautions</strong><br />Check with your doctor or pharmacist before taking Kromafina<br />٠ If you have ever had heart problems (e.g. congestive heart failure which causes shortness of breath and swollen ankles).<br />٠ If you have an uneven heart beat (arrhythmias).<br />٠ If you are allergic to medicines similar to ondansetron, such as granisetron orpalonosetron.<br />٠ If you have liver problems.<br />٠ If you have a blockage in your gut.</p><p>. If you have problems with the levels of salts in your blood, such as potassium, sodium and magnesium.<br />If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Kromafina.<br /><strong>Other medicines and Kromafina</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken or might take other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because Kromafina can affect the way some medicines work. Also some other medicines can affect the way Kromafina works.</p><p><br />In particular, tell your doctor or pharmacist if you are taking any of the following medicines:<br />٠ carbamazepine or phenytoin used to treat epilepsy.<br />٠ rifampicin used to treat infections such as tuberculosis (TB).<br />.antibiotics such as erythromycin or ketoconazole.<br />.anti-arrhythmic medicines used to treat an uneven heart-beat.<br />. beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines.<br />* tramadol, a pain killer.<br />٠ medicines that affect the heart (such as haloperidol or methadone).<br />٠ cancer medicines (especially anthracyclines and trastuzumab).<br />٠ SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram.<br />. SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine.</p><p><br />If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before having Kromaflna.</p><p><br /><strong>Pregnancy, breast feeding</strong><br />Do not use in the first trimester of pregnancy after discussion with your doctor of the potential benefits and risks to you and your unbom baby ofthe different treatment options. This is because Kromafina can slightly increase the risk of a baby being bom with cleft lip and/or cleft palate (openings or splits in the upper lip and/or the roof of the mouth). If you are already pregnant, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking Kromafina. If you are a woman of childbearing potential, you may be advised to use effective contraception.<br />Do not breast-feed if you are taking Kromafina. This is because small amounts pass into the mothers milk. Ask your doctor or midwife for advice<br />Important Information about some of the Ingredients of Kromaflna<br />This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, speak to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The dose you have been prescribed will depend on the treatment you are having.<br /><strong>To prevent nausea and vomiting from chemotherapy or radiotherapy</strong><br />On the day of chemotherapy or radiotherapy<br />٠the usual adult dose is 8 mg taken one to two hours before treatment and another 8 mg twelve hours after.<br />On the following days.<br />٠ the usual adult dose is 8mg twice a day.<br />٠ this may be given for up to 5 days.<br /><strong>Children aged over 6 months and adolescents:</strong><br />The doctor will decide the dose depending on the child&#39;s size (body surface area) or weight.<br />٠ the usual dose for a child is up to one 4mg twice a day.<br />. this can be given for up to 5 days<br /><strong>To prevent nausea and vomiting after an operation</strong><br />The usual adult dose is 16mg before your operation.</p><p>Children aged over 1 month and adolescents:</p><p>It is recommended that Kromaflna is given as an injection.</p><p><strong>Patients with moderate or severe liver problems</strong></p><p>The total daily dose should not be more than 8 mg.</p><p>Kromaflna should start to work within one or two hours of taking a dose</p><p><strong>If you are sick (vomit) within one hour of taking a dose</strong></p><p>٠ take the same dose again.</p><p>٠otherwise, do not take more Kromafina than the label says.</p><p>If you continue to feel sick, tell your doctor or nurse.</p><p><strong>If you take more Kromaflna than you should</strong></p><p>If you or your child take more Kromafina than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p><strong>If you forget to take Kromafina</strong></p><p>If you miss a dose and feel sick or vomit:</p><p>٠take Kromafina as soon as possible, then</p><p>* take your next dose at the usual time (as shown on the label)</p><p>٠do not take a double dose to make up for a forgotten dose.</p><p>If you miss a dose but do not feel sick</p><p>. take the next dose as shown on the label</p><p>. do not take a double dose to make up for a forgotten dose</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Kromafina </strong>can cause side effects, although not everybody gets them.</p><p><strong>Allergic reactions</strong></p><p>If you have an allergic reaction, stop taking it and see a doctor straight away.</p><p>The signs may include:</p><p>٠sudden wheezing and chest pain or chest tightness</p><p>٠swelling of your eyelids, face, lips, mouth or tongue</p><p>٠ skin rash - red spots or lumps under your skin (hives) anywhere on your body</p><p>٠ collapse.</p><p><strong>Other side effects include:</strong></p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>٠ headache.</p><p><strong>Common (may affect upto 1 in 10 people)</strong></p><p>٠a feeling of warmth or flushing</p><p>٠ constipation</p><p>٠ changes to liver function test results (if you take Kromafina with a medicine called cisplatin, otherwise this side effect is uncommon).</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>٠ hiccups</p><p>٠ low blood pressure, which can make you feel faint or dizzy</p><p>٠ uneven heart beat</p><p>٠chest pain</p><p>٠ fits</p><p>٠unusual body movements or shaking.</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>٠feeling dizzy or light headed</p><p>٠blurred vision</p><p>٠ disturbance in heart rhythm (sometimes causing a sudden loss of consciousness)</p><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><p>٠ poor vision or temporary loss of eyesight, which usually comes back within 20 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>٠ Keep this medicine out of the sight and reach of children.</p><p>٠ Do not use this medicine after the expiry date which is stated on the carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>٠ Store below 3O٠C</p><p>٠Do not use this medicine if you notice that the pack is changed or showing signs of tampering.</p><p>٠Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>٠ The active ingredient is ondansetron. Each Kromafina tablet contains ondansetron 4 mg or 8 mg.</p><p>. The other ingredients are: lactose, microcrystalline cellulose, pregelatinised maize starch, magnesium stearate, colloidal silicon dioxide, purified water and coated by yellow opadry.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ٠Kromafina tablets are yellow, oblong, film coated tablets and come in two
strengths.
٠ The 4 mg tablets contain 4 mg of the active ingredient ondansetron and are marked with " ل 513 on one face and plain on the other.
٠ The 8 mg tablets contain 8 mg of the active ingredient ondansetron and are marked with " ل 518 on one face and plain on the other.
٠ Kromaflna tablets come in:
blister packs of 10 tablets for each strength.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alpha Pharma</p><p>King Abdullah Economic City, Saudi Arabia</p><p>Email: regulatory@alphapharma.com.sa</p><p>Tel: +966 12 21 29013</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">كرومفينا يحتوي على مادة فعالة تسمى أوندانسيترون ، فهي تتتمي لمجموعة الأوية المسماة مضادات التقيوء-</p><p dir="RTL">كرومفينا يستخدم للحالات لتالية:</p><p dir="RTL">٠منع حالات الغثيان و التقيوء الناتجة عن العلاج الكيميائى (لدى الكبار و الأطفال) أو عن العلاج بالأشعة لمرضى</p><p dir="RTL">السرطان (لدى الكبار فقط(.</p><p dir="RTL">٠منع حالات الغثيان و التقيوء بعد العمليات الجراحية (لدى الكبار فقط(.</p><p dir="RTL">اسأل الطييب أو الصيلي الخاص بك إذا كنت ترغب في الحصول على اي شرح إضافي حول هذه الإستعمالات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتنارل كرومفينا في الحالات التالية:</p><p dir="RTL">٠ إذا كانت لديك حساسية تجاه أوندانسيترون أو أي من المكونات الأخرى لهذا الدواه (المدرجة في القسم ٦)</p><p dir="RTL">٠إذا كنت تتناول ابومورفين (يستعمل لعلاج مرض الباركينسون(</p><p dir="RTL">٠إذا كنت غير متاكد، تحدث مع الطبيب المعالج،أو الصيدلي قبل تناولك كرومفينا</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبييك المعلج أو الصيدلي قبل البدأ في استخدام كرومافينا:</p><p dir="RTL">٠إذا كنت قد عانيت فيما مضى مشاكل في القلب ( مثل قصور القلب الذي يؤدي إلى ضيق في التنفس و</p><p dir="RTL">إنتفاخ الكاحلين(</p><p dir="RTL">٠إذا كنت تعاني من عدم انتظام في ضربات القلب (عدم انتظام ضربات القلب(.</p><p dir="RTL">٠ إذا كان لديك حسلسية لأدوية مشابهة لأوندانسيترون، مل جراليسترون أو بالولوسيترون</p><p dir="RTL">٠إذاكان لديك مشاكل في الكبد</p><p dir="RTL">٠إذاكان لديك إنسداد في لأمعاء</p><p dir="RTL">٠ إذا كان لديك مشاكل في نسبة الأملاح في دمك، مثل البوتاسيوم، الصوديوم و المغنيسيرم.</p><p dir="RTL">إذا كنت غير واثقا فيما إذا كان أي مما ذكر اعلاه ينطبق عليك ، تحدث مع الطبيب المعالج،أو الصيدلي قبل</p><p dir="RTL">تئاولك كرومافينا.</p><p dir="RTL"><strong>كرومفينا والأدوية الأخرى</strong></p><p dir="RTL">اخبر الطبيب أو الصيدلي في حين تناولت أو كنت تتناول مؤخراً أو سوف تتناول أي ادوية أخرى. و هذا ينطبق</p><p dir="RTL">ايضا على الأدوية التي تقوم بشرائها بدون وصفة طبية و أيضا الأدوية العشبية. وذلك لأن كرومفينا قد يؤثر على</p><p dir="RTL">طريقة عمل بعض الأوية. كما أن بعض الأدوية الأخرى قد تؤثر على طريقة عمل كرومفينا.</p><p dir="RTL"><strong>يجب إبلاغ الطبيب أو الصيدلي إذا كنت تستخدم أيا من الأدوية التالية</strong><strong>:</strong></p><p dir="RTL">٠ كاربامازبين أو فينيتوين المستعملان لعلاج الصرع.</p><p dir="RTL">٠ ريفامبين المستعمل لعلاج الالتهابات مثل الدرن</p><p dir="RTL">٠ مضادات حيوية مثل إريثروميسين أو كيتوكونازول.</p><p dir="RTL">٠ أدوية مضاد اضطراب النظم، التي تستعمل لعلاج عدم إنتظام ضربات القلب.</p><p dir="RTL">٠ أدوية حاصرات بيتا المستخدمة لعلاج بعض مشاكل القلب أو العين أو القلق أو الوقاية من الصداع النصفي.</p><p dir="RTL">٠ ترامادول، مسكن الألم</p><p dir="RTL">٠الأدوية التي تؤثر على القلب (مثل هالوبيريدول أو الميثادون).</p><p dir="RTL">٠أدوية السرطان (خاصة أنثراسيكلين وتراستوزوماب).</p><p dir="RTL">٠مثبطات إعادة امتصاص السيروتونين الانتقائية (SSRIs) المستخدمة لعلاج الاكتئاب و/أو القلق بما في ذلك فلوكستين، باروكستين، سيرترالين، فلوفوكسامين، سيتالوبرام، إسيتالوبرام.</p><p dir="RTL">. SNRIs (مثبطات امتصاص السيروتونين والنورادرينالين) المستخدمة لعلاج الاكتئاب و/أو القلق بما في ذلك فينلافاكسين، دولوكستين.</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان أي مما سبق ينطبق عليك، تحدث مع طبيبك أو الصيدلي قبل تناول كرومافلنا.</p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية</strong></p><p dir="RTL">لا تستخدمه في الأشهر الثلاثة الأولى من الحمل بعد مناقشة مع طبيبك حول الفوائد والمخاطر المحتملة لك ولطفلك الذي لم يولد بعد من خيارات العلاج المختلفة. وذلك لأن كرومافينا يمكن أن يزيد قليلاً من خطر ولادة طفل بشفة مشقوقة و/أو حنك مشقوق (فتحات أو انشقاقات في الشفة العليا و/أو سقف الفم). إذا كنت حاملاً بالفعل، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فاطلبي المشورة من طبيبك أو الصيدلي قبل تناول كرومافينا. إذا كنت امرأة تتمتع بإمكانية الإنجاب، فقد يُنصح باستخدام وسائل منع الحمل الفعالة.</p><p dir="RTL">لا ترضعي إذا كنت تتناول كرومافينا. وذلك لأن كميات صغيرة تمر في حليب الأم. اسأل طبيبك أو القابلة للحصول على المشورة</p><p dir="RTL"><strong>معلومات هامة عن بعض مكونات كرومافلنا</strong></p><p dir="RTL">يحتوي هذا الدواء على اللاكتوز. إذا أخبرك طبيبك بأنك تعاني من عدم تحمل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا. تعتمد الجرعة الدوائية التي وصفت لك تتعلق بالعلاج الذي تاخذه.</p><p dir="RTL"><strong>لمنع الغثيان والقيء من العلاج الكيميائي أو العلاج الإشعاعي</strong></p><p dir="RTL">في يوم العلاج الكيميائي أو العلاج الإشعاعي</p><p dir="RTL">٠الجرعة الاعتيادية للكبار هي 8 ملغ تؤخذ قبل ساعة أو ساعتين من العلاج و8 ملغ أخرى بعد اثنتي عشرة ساعة.</p><p dir="RTL">في الأيام التالية:</p><p dir="RTL">٠الجرعة المعتادة للبالغين هي 8 ملجم مرتين في اليوم.</p><p dir="RTL">٠يمكن أن يعطى العلاج حتى 5 أيام.</p><p dir="RTL">الأطفال فوق 6 أشهر والمراهقين: يحدد الطبيب الجرعة الدوائية أخذ بعين الاعتبار حجم الطفل (مساحة الجسم) أوالوزن.</p><p dir="RTL">٠الجرعة المعتادة للطفل تصل إلى 4 مجم مرتين في اليوم.</p><p dir="RTL">٠يمكن أن يعطى العلاج حتى 5 أيام.</p><p dir="RTL"><strong>لمنع الغثيان والقيء بعد العملية</strong></p><p dir="RTL">الجرعة المعتادة للبالغين هي 16 مجم قبل العملية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال الذين تزيد أعمارهم عن شهر واحد و المراهقين:</p><p dir="RTL">ينصح بإعطائهم كرومافيناعن طريق الحقن.</p><p dir="RTL">المرضى الذين لديهم مشاكل معتلة أو شيدة في الكبد</p><p dir="RTL">الجرعة الدوائية اليومية الإجمالية يجب الا تتجاوز ٨ ملجم.</p><p dir="RTL">كرومافينا ييد أ مفعوله خلال ساعة أو ساعتين من تناول الجرعة الدوائية.</p><p dir="RTL"><strong>إذا تقيأت خلال ساعة من تناول الجرعة الدوائية</strong></p><p dir="RTL">٠تناول تفس الجرعة الدوائية مرة ثانية.</p><p dir="RTL">٠لا تتتاول كرومافينا أكثر مما اوصاك به الطبيب. إذا إستمر الشعور بالغثيان لديك، اخبرطبيبك أو الممرض.</p><p dir="RTL"><strong>إذاتنولت كرومافينا أكثر مما يجب:</strong></p><p dir="RTL">إذا تناولت أنت أو طفلك جرعة دوائية مفرطة من كرومافينا ، توجه حالاً للطبيب او لغرفة الطوارئ في</p><p dir="RTL">المستشفى وأحضر علبة الدواء معك</p><p dir="RTL"><strong>إذا نسيت أن تاخذ كرومافينا</strong><strong>:</strong></p><p dir="RTL">إذا نسيت الجرعة وكنت تشعر بغثيان أو تريد أن تتقيأ:</p><p dir="RTL">٠ تناول كرومافينا في أسرع ما يمكن، ومن ثم:</p><p dir="RTL">٠تناول القرص التالي الخاص بك في الموعد الإعتيادي.</p><p dir="RTL">٠لا تتناول جرعة دوائية مضاعفة للتعويض عن الجرعة الدوائية المنسية.</p><p dir="RTL">إذا نسيت جرعة دوانية لكنك لا تشعر بغثيان:</p><p dir="RTL">٠تناول الجرعة الدوائية التالية في الموعد الإعتيادي.</p><p dir="RTL">٠لا تتناول جرعة دوائية مضاعفة للتعويض عن الجرعة الدوانية المنسية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، إلا أنها قد لاتصيب الجميع.</p><p dir="RTL"><strong>ردود الغعل التحسسية:</strong></p><p dir="RTL">إذا حدث لديك رد فعل تحسسي، توقف عن العلاج بالدراء وراجع الطبيب حالا. هذه الأعراض ربما تكون:</p><p dir="RTL">٠صفير في التنفس وآلام في الصدر أو ضغط في الصدر.</p><p dir="RTL">٠إنتفاخ في الجفنين، في الوجه، في الشفتين، في الفم أو في لسانك.</p><p dir="RTL">٠طفح في الجلد نقاط حمراء أو كتل تحت جلدك (شرى) في كل مكان على سطح جسمك.</p><p dir="RTL">٠تدهور صحي.</p><p dir="RTL"><strong>أعراض جانبية إضافية</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة جدا (قد تصيب ما يزيد على ١من كل 10 أشخاص)</strong></p><p dir="RTL">٠صداع</p><p dir="RTL"><strong>شائعة (قد تظهر ما يزيد على ١من كل 10 أشخاص)</strong></p><p dir="RTL">٠الشعور بسخونة أو تورد.</p><p dir="RTL">٠إمساك</p><p dir="RTL">٠تغيرات في تتائج فحوصات وظائق الكبد (إذا كتت تتناول كرومافينا مع دواء يسمى سيسبلاتين، وإلا فإن</p><p dir="RTL">هدا العرض الجانبي غير شائع(.</p><p dir="RTL"><strong>غير شائعة (قد تظهر لدى ١من كل 100 أشخاص)</strong></p><p dir="RTL">٠فواق (الحازوقة(</p><p dir="RTL">٠ضغط دم منخفض، الذي قد يسبب لك الشعور بإغماء أو دوار.</p><p dir="RTL">٠عدم إنتظام نظم القلب (إضطرابات في نظم القلب(</p><p dir="RTL">٠ألم في الصدر.</p><p dir="RTL">٠إختلاجات (نوبات)</p><p dir="RTL">٠حركات شاذة للجسم أو إرتجاف.</p><p dir="RTL"><strong>نادرة (قد تظهرلدى على ١ شخص من بين 1000 شخص)</strong></p><p dir="RTL">٠الشعور بالدوخة أو الدوار.</p><p dir="RTL">٠ تشوش الرؤية.</p><p dir="RTL">٠ اضطراب في النظم القلبي (يسبب أحياناً فقدان الوعي بشكل مفاجئ(.</p><p dir="RTL"><strong>نادرة جدا (قد تظهرلدى على ١ شخص من بين 1000 شخص)</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">٠خلل في الرؤية أو فقدان مؤقت للرؤية، الذي عادة يعود خلال 20 دقيقه</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">٠قم بتخزين المستحضر بعيداً عن متناول الأطغال</p><p dir="RTL">٠لا تستعمل هذا المستحضر بعد انتهاء تاريخ الصلاحية والمذكور على الغلاف الخارجي و العبوة. تاريخ</p><p dir="RTL">انتهاء الصلاحية المذكور يعود إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">٠يخزن في درجة حرارة أقل من ٣٠ م</p><p dir="RTL">٠يجب عدم تناول كرومافينا اذا لاحظت علامات تشوه العبوة أوعلامات تمزق للعبوة.</p><p dir="RTL">٠لا تتخلص من أية أدوية في مياه الصرف الصحي او المخلفات المنزلية. اسأل الصيدلي عن كيفية</p><p dir="RTL">التخلص من الأدوية التي لم تعد في حاجة إليها. ستساعد هذه الإجراءات على حملية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على ماذا يحتوي كرومافينا</p><p dir="RTL">المادة الفعالة في كرومافينا أوندانسيترون. يحتوي كل قرص من كرومافينا على أوندانسيترون 4 ملجم أو 8 ملجم.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">لاكتوز ، سليولوز بلوري مكروي، نشا ذرة معدل، سترات مغنيسيوم، ثاتي أكسيد السيليكون و الماء. مغلفة بطبقة رقيقة من مادة الأوبدراي صفراء اللون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما هو شكل كرومافينا</p><p dir="RTL">أقراص كرومافينا صفراء بيضاوية الشكل مغلفة بغشاء وتأتي بتركيزن.</p><p dir="RTL">تحتوي الأقراص بتركيز ٤ ملجم على ٤ ملجم من ملدة أوندانسيترون الفعالة، ومنقوش عليها أ 13JS</p><p dir="RTL">من جانب وملساء من جانب الآخر.</p><p>٠&quot;JS تحتوي الأقراص بتركيز ٨ ملجم لى ٨ ملجم من مادة أوندانسيترون الفعالة، ومنقوش عليها أ 18</p><p dir="RTL">من جانب وملساء من جانب الآخر.</p><p dir="RTL">تتوفر أقراص كرومفينا ٤ ملجم و ٨ ملجم في عبوات تحتوي على ١٠ أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة المصنعة ومالك حق التسويق</p><p dir="RTL">ألفا فارما</p><p dir="RTL">مدينة الملك عيد الله الإقتصلدية - المملكة العريية السعودية</p><p>regulatory@alphapharma.com.sa: البريد الإلكتروني</p><p dir="RTL">للإبلاغ حول الأعراض الجانبية الثي قد تحدث</p><p dir="RTL">تلفون: 00966122129013</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KROMAFINA Film Coated Tablets 4 mg
KROMAFINA Film Coated Tablets 8 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains ondansetron 4 mg or 8 mg (as hydrochloride dihydrate).
Excipients with known effect: Contains Lactose (anhydrous) 80.50 mg or 161.00 mg
(see section 4.4).
For the full list of excipients see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kromafina tablets are yellow, oblong, film coated tablets and come in two strengths.
The 4 mg tablets contain 4 mg of the active ingredient ondansetron and are marked
with “JS13” on one face and plain on the other.
The 8 mg tablets contain 8 mg of the active ingredient ondansetron and are marked
with “JS18” on one face and plain on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults:</u><br />KROMAFINA tablets are indicated for the management of nausea and vomiting<br />induced by cytotoxic chemotherapy and radiotherapy.<br />KROMAFINA tablets are indicated for the prevention of post-operative nausea and<br />vomiting (PONV). For treatment of established PONV, administration by injection is<br />recommended.<br />&nbsp;</p><p><u>Paediatric Population:</u><br />KROMAFINA is indicated for the management of chemotherapy-induced nausea and<br />vomiting (CINV) in children aged &ge;6 months.<br />No studies have been conducted on the use of orally administered ondansetron in<br />the prevention and treatment of PONV in children aged &ge;1 month, administration by<br />IV injection is recommended for this purpose.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Chemotherapy and radiotherapy induced nausea and vomiting.</strong><br /><em>Adults:</em><br />The emetogenic potential of cancer treatment varies according to the doses and<br />combinations of chemotherapy and radiotherapy regimens used. The selection of<br />dose regimen should be determined by the severity of the emetogenic challenge.<br />Emetogenic Chemotherapy and Radiotherapy: KROMAFINA can be given either by<br />rectal, oral (tablets or syrup), intravenous or intramuscular administration.<br />For oral administration: 8mg taken 1 to 2 hours before chemotherapy or radiation<br />treatment, followed by 8 mg every 12 hours for a maximum of 5 days to protect<br />against delayed or prolonged emesis.<br />For highly emetogenic chemotherapy: a single dose of up to 24 mg KROMAFINA<br />taken with 12 mg oral dexamethasone sodium phosphate, 1 to 2 hours before<br />chemotherapy, may be used.<br />To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal<br />treatment with KROMAFINA may be continued for up to 5 days after a course of<br />treatment.<br />The recommended dose for oral administration is 8 mg to be taken twice daily.</p><p><em>Paediatric Population:<br />CINV in children aged &ge; 6 months and adolescents</em><br />The dose for CINV can be calculated based on body surface area (BSA) or weight &ndash;<br />see below. In paediatric clinical studies, ondansetron was given by IV infusion diluted<br />in 25 to 50 mL of saline or other compatible infusion fluid and infused over not less<br />than 15 minutes.<br />Weight-based dosing results in higher total daily doses compared to BSA-based<br />dosing (see section 4.4).<br />There are no data from controlled clinical trials on the use of KROMAFINA in the<br />prevention of delayed or prolonged CINV. There are no data from controlled clinical<br />trials on the use of KROMAFINA for radiotherapy-induced nausea and vomiting in<br />children.<br /><em>Dosing by BSA:</em><br />KROMAFINA should be administered immediately before chemotherapy as a single<br />intravenous dose of 5 mg/m2. The single intravenous dose must not exceed 8 mg.</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days<br />(Table 1).<br />The total dose over 24 hours (given as divided doses) must not exceed adult dose of<br />32 mg.</p><p><u>Table 1: BSA-based dosing for Chemotherapy - Children aged &ge; 6 months and<br />adolescents</u></p><p><u><img alt="" width="803" height="171" src="data:image/png;base64,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" /></u></p><p>a The intravenous dose must not exceed 8 mg.<br />b The total dose over 24 hours (given as divided doses) must not exceed adult dose<br />of 32 mg</p><p><em>Dosing by bodyweight:</em><br />Weight-based dosing results in higher total daily doses compared to BSA-based<br />dosing (see sections 4.4. and 5.1).<br />KROMAFINA should be administered immediately before chemotherapy as a single<br />intravenous dose of 0.15 mg/kg. The single intravenous dose must not exceed 8 mg.<br />Two further intravenous doses may be given in 4-hourly intervals.<br />Oral dosing can commence 12 hours later and may be continued for up to 5 days<br />(Table 2).<br />The total dose over 24 hours (given as divided doses) must not exceed adult dose of<br />32 mg.</p><p><u>Table 2: Weight-based dosing for Chemotherapy - Children aged &ge;6 months and<br />adolescents</u></p><p><u><img alt="" width="807" height="128" src="data:image/png;base64,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" /></u></p><p>a The intravenous dose must not exceed 8 mg.<br />b The total dose over 24 hours (given as divided doses) must not exceed adult dose<br />of 32 mg.</p><p><u>Elderly:</u><br />No alteration of oral dose or frequency of administration is required.<br />Patients with Renal Impairment:<br />No alteration of daily dosage or frequency of dosing, or route of administration are<br />required.<br />&nbsp;</p><p><u>Patients with Hepatic Impairment:</u><br />Clearance of KROMAFINA is significantly reduced and serum half-life significantly<br />prolonged in subjects with moderate or severe impairment of hepatic function. In<br />such patients a total daily dose of 8 mg should not be exceeded.<br />Patients with Poor Sparteine/Debrisoquine Metabolism:<br />The elimination half-life of ondansetron is not altered in subjects classified as poor<br />metabolisers of sparteine and debrisoquine. Consequently in such patients repeat<br />dosing will give drug exposure levels no different from those of the general<br />population. No alteration of daily dosage or frequency of dosing is required.<br />Post operative nausea and vomiting (PONV):<br />&nbsp;</p><p><em>Adults:</em><br />For the prevention of PONV: KROMAFINA can be administered orally or by<br />intravenous or intramuscular injection.<br />For oral administration: 16 mg taken one hour prior to anaesthesia.<br />For the treatment of established PONV: Intravenous or intramuscular administration<br />is recommended.<br />&nbsp;</p><p><em>Paediatric population:</em><br />PONV in children aged &ge; 1 month and adolescents<br /><u>Oral formulation:</u><br />No studies have been conducted on the use of orally administered ondansetron in<br />the prevention or treatment of post-operative nausea and vomiting; slow IV injection<br />(not less than 30 seconds) is recommended for this purpose.<br /><u>Injection:</u><br />For prevention of PONV in paediatric patients having surgery performed under<br />general anaesthesia, a single dose of ondansetron may be administered by slow<br />intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a<br />maximum of 4 mg either prior to, at or after induction of anaesthesia.</p><p>For the treatment of PONV after surgery in paediatric patients having surgery<br />performed under general anaesthesia, a single dose of KROMAFINA may be<br />administered by slow intravenous injection (not less than 30 seconds) at a dose of<br />0.1 mg/kg up to a maximum of 4 mg.<br />There are no data on the use of KROMAFINA in the treatment of PONV in children<br />below 2 years of age.<br />&nbsp;</p><p><em>Elderly:</em><br />There is limited experience in the use of KROMAFINA in the prevention and<br />treatment of post-operative nausea and vomiting in the elderly, however<br />KROMAFINA is well tolerated in patients over 65 years receiving chemotherapy.<br />Patients with Renal impairment:<br />No alteration of daily dosage or frequency of dosing, or route of administration are<br />required.<br />&nbsp;</p><p><em>Patients with Hepatic impairment:</em><br />Clearance of KROMAFINA is significantly reduced and serum half life significantly<br />prolonged in subjects with moderate or severe impairment of hepatic function. In<br />such patients a total daily dose of 8 mg should not be exceeded.<br />&nbsp;</p><p><em>Patients with poor Sparteine/Debrisoquine Metabolism:</em><br />The elimination half-life of ondansetron is not altered in subjects classified as poor<br />metabolisers of sparteine and debrisoquine. Consequently in such patients repeat<br />dosing will give drug exposure levels no different from those of the general<br />population. No alteration of daily dosage or frequency of dosing is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concomitant use with apomorphine (see section 4.5) Hypersensitivity to any
component of the preparation
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited<br />hypersensitivity to other selective 5HT3 receptor antagonists. Respiratory events<br />should be treated symptomatically and clinicians should pay particular attention to<br />them as precursors of hypersensitivity reactions.<br />Ondansetron prolongs the QT interval in a dose-dependent manner (see section<br />5.1). In addition, post- marketing cases of Torsade de Pointes have been reported in</p><p>patients using ondansetron. Avoid ondansetron in patients with congenital long QT<br />syndrome. Ondansetron should be administered with caution to patients who have or<br />may develop prolongation of QTc, including patients with electrolyte abnormalities,<br />congestive heart failure, bradyarrhythmias or patients taking other medicinal<br />products that lead to QT prolongation or electrolyte abnormalities.<br />Hypokalaemia and hypomagnesaemia should be corrected prior to ondansetron<br />administration.<br />There have been post-marketing reports describing patients with serotonin syndrome<br />(including altered mental status, autonomic instability and neuromuscular<br />abnormalities) following the concomitant use of ondansetron and other serotonergic<br />drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin<br />noradrenaline reuptake inhibitors (SNRIs)). If concomitant treatment with<br />ondansetron and other serotonergic drugs is clinically warranted, appropriate<br />observation of the patient is advised.<br />As ondansetron is known to increase large bowel transit time, patients with signs of<br />subacute intestinal obstruction should be monitored following administration.<br />In patients with adenotonsillar surgery prevention of nausea and vomiting with<br />ondansetron may mask occult bleeding. Therefore, such patients should be followed<br />carefully after ondansetron.<br />Patients with rare hereditary problems of galactose intolerance, Lapp lactasedeficiency<br />or glucose- galactose malabsorption should not take this medicine.<br />&nbsp;</p><p><u>Paediatric Population:</u><br />Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents<br />should be monitored closely for impaired hepatic function.<br />&nbsp;</p><p><u>CINV: </u>When calculating the dose on an mg/kg basis and administering three doses<br />at 4-hour intervals, the total daily dose will be higher than if one single dose of 5<br />mg/m2 followed by an oral dose is given. The comparative efficacy of these two<br />different dosing regimens has not been investigated in clinical trials. Cross-trial<br />comparison indicates similar efficacy for both regimens (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that ondansetron either induces or inhibits the metabolism of<br />other drugs commonly coadministered with it. Specific studies have shown that there<br />are no interactions when ondansetron is administered with alcohol, temazepam,<br />furosemide, alfentanil, tramadol, morphine, lidocaine, thiopental, or propofol.<br />Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes:<br />CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes</p><p>capable of metabolising ondansetron, enzyme inhibition or reduced activity of one<br />enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other<br />enzymes and should result in little or no significant change in overall ondansetron<br />clearance or dose requirement.<br />Caution should be exercised when ondansetron is coadministered with drugs that<br />prolong the QT interval and/or cause electrolyte abnormalities (see section 4.4).<br />Use of ondansetron with QT prolonging drugs may result in additional QT<br />prolongation. Concomitant use of ondansetron with cardiotoxic drugs (e.g.<br />anthracyclines (such as doxorubicin, daunorubicin) or trastuzumab), antibiotics (such<br />as erythromycin), antifungals (such as ketoconazole), antiarrhythmics (such as<br />amiodarone) and beta blockers (such as atenolol or timolol) may increase the risk of<br />arrhythmias. (See section 4.4).<br /><em>Serotonergic Drugs (e.g. SSRIs and SNRIs): </em>There have been post-marketing<br />reports describing patients with serotonin syndrome (including altered mental status,<br />autonomic instability and neuromuscular abnormalities) following the concomitant<br />use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs) (see<br />section 4.4).<br /><em>Apomorphine</em>: Based on reports of profound hypotension and loss of consciousness<br />when ondansetron was administered with apomorphine hydrochloride, concomitant<br />use with apomorphine is contraindicated.<br /><em>Phenytoin, Carbamazepine and Rifampicin: </em>In patients treated with potent inducers<br />of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin), the oral clearance of<br />ondansetron was increased and ondansetron blood concentrations were decreased.<br />Tramadol: Data from small studies indicate that ondansetron may reduce the<br />analgesic effect of tramadol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u><br />Women of childbearing potential should consider the use of contraception.<br />&nbsp;</p><p><u>Pregnancy</u><br />Based on human experience from epidemiological studies, ondansetron is suspected<br />to cause orofacial malformations when administered during the first trimester of<br />pregnancy.<br />In one cohort study including 1.8 million pregnancies, first trimester ondansetron use<br />was associated with an increased risk of oral clefts (3 additional cases per 10 000<br />women treated; adjusted relative risk, 1.24, (95% CI 1.03-1.48)).</p><p>The available epidemiological studies on cardiac malformations show conflicting<br />results.<br />Animal studies does not indicate direct or indirect harmful effects with respect to<br />reproductive toxicity.<br />Ondansetron should not be used during the first trimester of pregnancy.<br />&nbsp;</p><p><u>Breast-feeding</u><br />Tests have shown that ondansetron passes into the milk of lactating animals. It is<br />therefore recommended that mothers receiving KROMAFINA should not breast-feed<br />their babies.<br />&nbsp;</p><p><u>Fertility</u><br />There is no information on the effects of ondansetron on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In psychomotor testing ondansetron does not impair performance nor cause<br />sedation. No detrimental effects on such activities are predicted from the<br />pharmacology of ondansetron.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events are listed below by system organ class and frequency. Frequencies<br />are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon<br />(&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1000) and very rare (&lt;1/10,000). Very<br />common, common and uncommon events were generally determined from clinical<br />trial data. The incidence in placebo was taken into account. Rare and very rare<br />events were generally determined from post-marketing spontaneous data.<br />The following frequencies are estimated at the standard recommended doses of<br />ondansetron. The adverse event profiles in children and adolescents were<br />comparable to that seen in adults.</p><p><strong>Immune system disorders</strong><br />Rare: Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.</p><p><strong>Nervous system disorders</strong><br />Very common: Headache.<br />Uncommon: Seizures, movement disorders (including extrapyramidal reactions such as dystonic<br />reactions, oculogyric crisis and dyskinesia) (1).<br />Rare: Dizziness predominantly during rapid IV administration.</p><p><strong>Eye disorders</strong><br />Rare: Transient visual disturbances (eg. blurred vision) predominantly during IV<br />administration.<br />Very rare: Transient blindness predominantly during IV administration (2).</p><p><strong>Cardiac disorders</strong><br />Uncommon: Arrhythmias, chest pain with or without ST segment depression, bradycardia.<br />Rare: QTc prolongation (including Torsade de Pointes).<br />&nbsp;</p><p><strong>Vascular disorders</strong><br />Common: Sensation of warmth or flushing.<br />Uncommon: Hypotension.<br />&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong><br />Uncommon: Hiccups.<br />&nbsp;</p><p><strong>Gastrointestinal disorders</strong><br />Common: Constipation.<br />&nbsp;</p><p><strong>Hepatobiliary disorders</strong><br />Uncommon: Asymptomatic increases in liver function tests (3).<br />1. Observed without definitive evidence of persistent clinical sequelae.<br />2. The majority of the blindness cases reported resolved within 20 minutes. Most<br />patients had received chemotherapeutic agents, which included cisplatin. Some<br />cases of transient blindness were reported as cortical in origin.<br />3. These events were observed commonly in patients receiving chemotherapy with<br />cisplatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and Signs</u><br />There is limited experience of ondansetron overdose. In the majority of cases,<br />symptoms were similar to those already reported in patients receiving recommended<br />doses (see section 4.8). Manifestations that have been reported include visual<br />disturbances, severe constipation, hypotension and a vasovagal episode with<br />transient second-degree AV block<br />Ondansetron prolongs the QT interval in a dose-dependent fashion. ECG monitoring<br />is recommended in cases of overdose.<br />&nbsp;</p><p><u>Paediatric population</u><br />Paediatric cases consistent with serotonin syndrome have been reported after<br />inadvertent oral overdoses of ondansetron (exceeded estimated ingestion of 4<br />mg/kg) in infants and children aged 12 months to 2 years.<br />&nbsp;</p><p><u>Treatment</u><br />There is no specific antidote for ondansetron, therefore in all cases of suspected<br />overdose, symptomatic and supportive therapy should be given as appropriate.<br />Further management should be as clinically indicated or as recommended by the<br />national poisons centre, where available.<br />The use of ipecacuanha to treat overdose with ondansetron is not recommended, as<br />patients are unlikely to respond due to the anti-emetic action of ondansetron itself.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mechanism of Action</u><br />Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode<br />of action in the control of nausea and vomiting is not known. Chemotherapeutic<br />agents and radiotherapy may cause release of 5HT in the small intestine initiating a<br />vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks</p><p>the initiation of this reflex. Activation of vagal afferents may also cause a release of<br />5HT in the area postrema, located on the floor of the fourth ventricle, and this may<br />also promote emesis through a central mechanism. Thus, the effect of ondansetron<br />in the management of the nausea and vomiting induced by cytotoxic chemotherapy<br />and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons<br />located both in the peripheral and central nervous system.<br />The mechanisms of action in post-operative nausea and vomiting are not known but<br />there may be common pathways with cytotoxic induced nausea and vomiting.<br />Ondansetron does not alter plasma prolactin concentrations.<br />The role of ondansetron in opiate-induced emesis is not yet established.</p><p><u>QT Prolongation</u><br />The effect of ondansetron on the QTc interval was evaluated in a double blind,<br />randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58<br />healthy adult men and women.<br />Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes.<br />At the highest tested dose of 32 mg, the maximum mean (upper limit of 90% CI)<br />difference in QTcF from placebo after baseline-correction was 19.6 (21.5) msec. At<br />the lower tested dose of 8 mg, the maximum mean (upper limit of 90% CI) difference<br />in QTcF from placebo after baseline-correction was 5.8 (7.8) msec. In this study,<br />there were no QTcF measurements greater than 480 msec and no QTcF<br />prolongation was greater than 60 msec.</p><p><u>Paediatric population:<br />CINV</u><br />The efficacy of ondansetron in the control of emesis and nausea induced by cancer<br />chemotherapy was assessed in a double-blind randomised trial in 415 patients aged<br />1 to 18 years (S3AB3006). On the days of chemotherapy, patients received either<br />ondansetron 5 mg/m2 intravenous and ondansetron 4 mg orally after 8 to 12 hours or<br />ondansetron 0.45 mg/kg intravenous and placebo orally after 8 to 12 hours. Postchemotherapy<br />both groups received 4 mg ondansetron syrup twice daily for 3 days.<br />Complete control of emesis on worst day of chemotherapy was 49% (5<br />mg/m2 intravenous and ondansetron 4 mg orally) and 41% (0.45 mg/kg intravenous<br />and placebo orally). Post-chemotherapy both groups received 4 mg ondansetron<br />syrup twice daily for 3 days. There was no difference in the overall incidence or<br />nature of adverse events between the two treatment groups.<br />A double-blind randomised placebo-controlled trial (S3AB4003) in 438 patients aged<br />1 to 17 years demonstrated complete control of emesis on worst day of<br />chemotherapy in:</p><p>&bull; 73% of patients when ondansetron was administered intravenously at a dose of 5<br />mg/m2 intravenous together with 2 to 4 mg dexamethasone orally<br />&bull; 71% of patients when ondansetron was administered as syrup at a dose of 8 mg<br />together with 2 to 4 mg dexamethasone orally on the days of chemotherapy.<br />Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 2<br />days. There was no difference in the overall incidence or nature of adverse events<br />between the two treatment groups.<br />The efficacy of ondansetron in 75 children aged 6 to 48 months was investigated in<br />an open-label, non-comparative, single-arm study (S3A40320). All children received<br />three 0.15 mg/kg doses of intravenous ondansetron, administered 30 minutes before<br />the start of chemotherapy and then at 4 and 8 hours after the first dose. Complete<br />control of emesis was achieved in 56% of patients.<br />Another open-label, non-comparative, single-arm study (S3A239) investigated the<br />efficacy of one intravenous dose of 0.15 mg/kg ondansetron followed by two oral<br />ondansetron doses of 4 mg for children aged &lt; 12 years and 8 mg for children aged<br />&ge; 12 years (total no. of children n = 28). Complete control of emesis was achieved in<br />42% of patients.<br />&nbsp;</p><p><u>PONV</u><br />The efficacy of a single dose of ondansetron in the prevention of post-operative<br />nausea and vomiting was investigated in a randomised, double-blind, placebocontrolled<br />study in 670 children aged 1 to 24 months (post-conceptual age &ge; 44<br />weeks, weight &ge; 3 kg). Included subjects were scheduled to undergo elective surgery<br />under general anaesthesia and had an ASA status &le; III. A single dose of<br />ondansetron 0.1 mg/kg was administered within five minutes following induction of<br />anaesthesia. The proportion of subjects who experienced at least one emetic<br />episode during the 24-hour assessment period (ITT) was greater for patients on<br />placebo than those receiving ondansetron (28% vs. 11%, p &lt;0.0001).<br />Four double-blind, placebo-controlled studies have been performed in 1469 male<br />and female patients (2 to 12 years of age) undergoing general anaesthesia. Patients<br />were randomised to either single intravenous doses of ondansetron (0.1 mg/kg for<br />paediatric patients weighing 40 kg or less, 4 mg for paediatric patients weighing<br />more than 40 kg; number of patients = 735) or placebo (number of patients = 734).<br />Study drug was administered over at least 30 seconds, immediately prior to or<br />following anaesthesia induction. Ondansetron was significantly more effective than<br />placebo in preventing nausea and vomiting. The results of these studies are<br />summarised in Table 3.</p><p><img src="data:image/png;base64,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" alt="" width="815" height="243" vspace="0" hspace="0" border="0" style="width:815px;height:243px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following oral administration, ondansetron is passively and completely absorbed<br />from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma<br />concentrations of about 30 ng/mL are attained approximately 1.5 hours after an 8 mg<br />dose. For doses above 8 mg the increase in ondansetron systemic exposure with<br />dose is greater than proportional; this may reflect some reduction in first pass<br />metabolism at higher oral doses. Mean bioavailability in healthy male subjects,<br />following the oral administration of a single 8 mg tablet, is approximately 55 to 60%.<br />Bioavailability, following oral administration, is slightly enhanced by the presence of<br />food but unaffected by antacids.<br />The disposition of ondansetron following oral, intramuscular (IM) and intravenous<br />(IV) dosing is similar with a terminal half life of about 3 hours and steady state<br />volume of distribution of about 140 L. Equivalent systemic exposure is achieved after<br />IM and IV administration of ondansetron.<br />A 4mg intravenous infusion of ondansetron given over 5 minutes results in peak<br />plasma concentrations of about 65 ng/mL. Following intramuscular administration of<br />ondansetron, peak plasma concentrations of about 25 ng/mL are attained within 10<br />minutes of injection.<br />Following administration of ondansetron suppository, plasma ondansetron<br />concentrations become detectable between 15 and 60 minutes after dosing.<br />Concentrations rise in an essentially linear fashion, until peak concentrations of 20-<br />30 ng/mL are attained, typically 6 hours after dosing. Plasma concentrations then<br />fall, but at a slower rate than observed following oral dosing due to continued<br />absorption of ondansetron. The absolute bioavailability of ondansetron from the<br />suppository is approximately 60% and is not affected by gender. The half life of the<br />elimination phase following suppository administration is determined by the rate of<br />ondansetron absorption, not systemic clearance and is approximately 6 hours.<br />Females show a small, clinically insignificant, increase in half-life in comparison with<br />males.</p><p>Ondansetron is not highly protein bound (70-76%). Ondansetron is cleared from the<br />systemic circulation predominantly by hepatic metabolism through multiple<br />enzymatic pathways. Less than 5% of the absorbed dose is excreted unchanged in<br />the urine. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism)<br />has no effect on ondansetron&#39;s pharmacokinetics. The pharmacokinetic properties of<br />ondansetron are unchanged on repeat dosing.</p><p><u>Special Patient Populations:</u><br /><em>Gender</em><br />Gender differences were shown in the disposition of ondansetron, with females<br />having a greater rate and extent of absorption following an oral dose and reduced<br />systemic clearance and volume of distribution (adjusted for weight).<br />&nbsp;</p><p><em>Children and Adolescents (aged 1 month to 17 years)</em><br />In paediatric patients aged 1 to 4 months (n=19) undergoing surgery, weight<br />normalised clearance was approximately 30% slower than in patients aged 5 to 24<br />months (n=22) but comparable to the patients aged 3 to 12 years. The half-life in the<br />patient population aged 1 to 4 month was reported to average 6.7 hours compared to<br />2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. The<br />differences in pharmacokinetic parameters in the 1 to 4 month patient population can<br />be explained in part by the higher percentage of total body water in neonates and<br />infants and a higher volume of distribution for water soluble drugs like ondansetron.<br />In paediatric patients aged 3 to 12 years undergoing elective surgery with general<br />anaesthesia, the absolute values for both the clearance and volume of distribution of<br />ondansetron were reduced in comparison to values with adult patients. Both<br />parameters increased in a linear fashion with weight and by 12 years of age, the<br />values were approaching those of young adults. When clearance and volume of<br />distribution values were normalised by body weight, the values for these parameters<br />were similar between the different age group populations. Use of weight-based<br />dosing compensates for age- related changes and is effective in normalising<br />systemic exposure in paediatric patients.<br />Population pharmacokinetic analysis was performed on 428 subjects (cancer<br />patients, surgery patients and healthy volunteers) aged 1 month to 44 years<br />following intravenous administration of ondansetron. Based on this analysis,<br />systemic exposure (AUC) of ondansetron following oral or IV dosing in children and<br />adolescents was comparable to adults, with the exception of infants aged 1 to 4<br />months. Volume was related to age and was lower in adults than in infants and<br />children. Clearance was related to weight but not to age with the exception of infants<br />aged 1 to 4 months. It is difficult to conclude whether there was an additional<br />reduction in clearance related to age in infants 1 to 4 months or simply inherent<br />variability due to the low number of subjects studied in this age group. Since patients</p><p>less than 6 months of age will only receive a single dose in PONV a decreased<br />clearance is not likely to be clinically relevant.<br />&nbsp;</p><p><em>Elderly</em><br />Early Phase I studies in healthy elderly volunteers showed a slight age-related<br />decrease in clearance, and an increase in half-life of ondansetron. However, wide<br />inter-subject variability resulted in considerable overlap in pharmacokinetic<br />parameters between young (&lt; 65 years of age) and elderly subjects (&ge; 65 years of<br />age) and there were no overall differences in safety or efficacy observed between<br />young and elderly cancer patients enrolled in CINV clinical trials to support a<br />different dosing recommendation for the elderly.<br />Based on more recent ondansetron plasma concentrations and exposure-response<br />modelling, a greater effect on QTcF is predicted in patients &ge;75 years of age<br />compared to young adults. Specific dosing information is provided for patients over<br />65 years of age and over 75 years of age for intravenous dosing.<br />&nbsp;</p><p><em>Renal impairment</em><br />In patients with renal impairment (creatinine clearance 15-60 mL/min), both systemic<br />clearance and volume of distribution are reduced following IV administration of<br />ondansetron, resulting in a slight, but clinically insignificant, increase in elimination<br />half-life (5.4 hours). A study in patients with severe renal impairment who required<br />regular haemodialysis (studied between dialyses) showed ondansetron&#39;s<br />pharmacokinetics to be essentially unchanged following IV administration.<br />&nbsp;</p><p><em>Hepatic impairment</em><br />Following oral, intravenous or intramuscular dosing in patients with severe hepatic<br />impairment, ondansetron&#39;s systemic clearance is markedly reduced with prolonged<br />elimination half-lives (15-32 hours) and an oral bioavailability approaching 100% due<br />to reduced pre-systemic metabolism. The pharmacokinetics of ondansetron following<br />administration as a suppository have not been evaluated in patients with hepatic<br />impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No additional data of relevance</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ANHYDROUS LACTOSE<br />MICROCRYSTALLINE CELLULOSE<br />PARTIALLY PREGELATINIZED MAIZE<br />STARCH<br />COLLOIDAL SILLCONE DIOXIDE<br />MAGNESIUM STEARATE<br />PURIFIED WATER<br />OPADRY 03B52375 YELLOW &ndash; Coating Material</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years (24 Months).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>KROMAFINA Tablets 4mg come in blister packs of 10 tablets comprising<br />aluminium/PVC blister film and aluminium foil lidding.<br />KROMAFINA Tablets 8mg come in blister packs of 10 tablets comprising<br />aluminium/PVC blister film and aluminium foil lidding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in<br />accordance with local requirements, Keep out of the reach &amp; sight of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alpha pharma,
King Abdullah economic city, Rabigh, Kingdom of SAUDI ARABIA
P.O. Box 23989-6704
Tel: +966 12 21 29013
For any information about this medicinal product, please contact the Regulatory
affairs department of authorization holder:
Saudi Arabia
Regulatory affairs department
Riyadh
Tel: +966112931722 Ex:102 - 104
Email: regulatory@alphapharma.com.sa
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08.07.2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>